Integ. Proteins (519606)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Looking at Integ. Proteins, I am reminded of Graham's warning: you are neither right nor wrong because the crowd disagrees; you are right because your facts are right. Here the facts are alarming. The company had sales of ₹0 Cr in the latest quarter, sales growth of -100%, and profit growth of -128.57%. A business with no revenue is a business, but not one I can value with a P/E of 291.79; that multiple is meaningless, built on a sliver of earnings. Meanwhile, I am asked to pay ₹21.93 per share, 19.24 times book value, for a company whose book value is just ₹1.14. Benjamin Graham would demand a margin of safety; I see the opposite. ROCE is only 1.87%, and the Piotroski F-Score of 3/9 indicates very weak financial health. The return on equity of 9.58% looks respectable, but on this tiny base, with no sales, it does not compensate. The 52-week range shows the price has fallen from ₹136.95 to ₹21.93, an 84% decline. Markets are forward-looking, but a falling knife without earnings is still dangerous. There is no dividend yield to reward patient holding, and promoter holding is not disclosed, so I cannot judge alignment. FairStock says insufficient data; I agree. This is not an investment in a wonderful franchise at a fair price; it is a speculation on a potential turnaround. I do not speculate with capital I need to preserve. I will only reconsider when the company shows real sales, positive profits, and honest financials.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer